Management of lung cancer patients' quality of life in clinical practice: a Delphi study

Abstract

Background The assessment of health-related quality of life (HRQoL) has seen exponential growth in oncology clinical trials. However, the measurement of HRQoL has yet to be optimised in routine clinical practice. This study aimed at exploring the operationalisation of HRQoL in clinical practice with the goal of reaching a consensus from a panel of physicians. Materials and methods Physicians involved in the management of lung cancer patients in France were recruited to participate in a Delphi study. The study involved three rounds of iterated queries to gain consensus on management aspects of HRQoL, including timing of discussion on HRQoL, which specific domains of HRQoL should be discussed, and what was the most appropriate method of assessment. The threshold adopted for consensus was at least 70% agreement among physicians. A scientific committee reviewed results following each round of the Delphi study. Results A representative panel of 60 physicians participated in this study. Consensus was obtained for HRQoL management at all time points in the patient care pathway. Panellists agreed that HRQoL discussions should occur during routine visits and hospitalisation. The involvement of patients' relatives was also recognised as important, except when discussing side-effects and involvement of a multidisciplinary team. There was a lack of consensus on a systematic assessment for all patients at each visit and no consensus on how HRQoL should be measured in clinical practice. Conclusions HRQoL discussions are considered an integral part in the management of lung cancer patients, and are deemed key to success in patient–physician interaction. Further research is required to harmonise how best to implement HRQoL assessment.

A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer

“…Patients often face a burden of symptoms and side effects during antitumor therapy, which greatly reduces their quality of life and affects their treatment compliance. Therefore, adverse reaction management is essential in improving medication compliance and optimizing HRQOL ( 41 ). It is necessary to conduct whole-process management of patients on the occurrence of adverse reactions and their quality of life.…”

A Delphi Study of Expert Consensus on Chinese Medicine Syndrome Differentiation and Herbal Use for Early Breast Cancer

“… 6 , 9 This study reports the conduct and findings of the expert survey. The Delphi method has been widely used to gain consensus in health research, 10 - 13 including for CM syndromes in breast cancer. Delphi studies by Guan 14 and Guo 15 focussed on the different treatment stages in early breast cancer, and the latter involved the same experts in each of the different rounds.…”